Epclusa (sofosbuvir and velpatasvir)
What is Epclusa?
On June 28, 2016 the U.S. Food and Drug Administration approved the prescription medication Epclusa® (sofosbuvir and velpatasvir). Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for ribavirin.
The active ingredients of Epclusa are 400 mg sofosbuvir and 100 mg velpatasvir.
Regarding efficacy, of the 1,035 patients treated with Epclusa for 12 weeks in the clinical studies, 98 percent achieved sustained virologic response (SVR). Patients with decompensated cirrhosis receiving Epclusa with ribavirin for 12 weeks achieved a high SVR rate (94 percent) compared to those who received Epclusa for 12 weeks or 24 weeks (83 percent and 86 percent, respectively).
Last Updated: June 2016
"Co-pay Coupon | EPCLUSA®." Gilead.com. Gilead Sciences, Inc., https://www.epclusainfo.com/co-pay-coupon-registration. Retrieved June 29, 2016
"Highlights of Prescribing Information." FDA.gov. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf. Retrieved June 29, 2016.
"Support Path Harvoni® and Epclusa® Tablets Treatment Support." Gilead.com. Gilead Sciences, Inc., http://www.mysupportpath.com/. Retrieved June 29, 2016.
"U.S. Food and Drug Administration Approves Gilead's Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C. Gilead.com". http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&. Retrieved June 29, 2016.